Should I Buy HCAT? HCAT 2026 Analysis

Should You Buy Health Catalyst Inc (HCAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

2.150

1 Day change

2.87%

52 Week Range

5.860

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: trend is bearish (SMA_200 > SMA_20 > SMA_5) and momentum is deteriorating (MACD histogram negative and expanding).
Near-term edge is weak: pattern-based forecast points to slightly negative drift over 1D/1W/1M (-0.31% / -0.29% / -1.44%).
Sentiment headwinds: insiders are selling aggressively (+869% last month), while analysts remain Neutral/Hold with repeated price-target cuts.
Upside case relies mainly on a support bounce near ~$2.13, but there’s no proprietary buy signal to justify acting now.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Price: 2.17 (closed) vs prev close 2.18 (-0.69%); small post-market uptick (+0.23%) doesn’t change the downtrend picture.
Trend: Bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) indicates persistent longer-term downtrend.
Momentum: MACD histogram -0.00169 (below 0) and negatively expanding → bearish momentum strengthening.
RSI(6): 40.555 (neutral-to-weak) → not oversold enough to suggest a high-conviction mean reversion.
Levels: Support S1 ~2.13 (nearby), then S2 ~2.051; resistance Pivot ~2.258 then R1 ~2.386. Current price sits below the pivot, so rallies likely face overhead supply.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Put/Call OI ratio 0.53 (more call OI than put OI) → mildly bullish longer-dated positioning.
Activity: Very light volume (calls 22, puts 0) → today’s tape provides little real-time sentiment signal.
Volatility: 30D IV 53.36 vs HV 52.5 (roughly in-line); IV percentile 14.34 / IV rank 10.14 → options are relatively “cheap” vs its own history, but low IV alone isn’t a buy trigger.
Net takeaway: Options positioning is not strongly bearish, but the lack of put volume and low overall activity reduces confidence that options traders are signaling an imminent upside move.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-26 (after hours) could reset expectations if margins/EBITDA progression shows up.
- Operating improvement trend (from last reported quarter): gross margin improved (+8.25% YoY) and losses narrowed (net income and EPS improved YoY).
- Options IV rank/percentile are low, which can be favorable if a positive catalyst emerges (less “priced-in” volatility).

Neutral/Negative Catalysts

- Technical trend remains bearish (downtrend MA structure + weakening MACD), reducing odds of a sustained rally without a catalyst.
- Insider selling is elevated (selling amount up 869.22% over the last month) → negative signal for near-term confidence.
- Analyst narrative: multiple price-target cuts and “no near-term catalysts” framing.
- No supportive news flow in the last week to change sentiment.
- Market backdrop risk: S&P 500 down -0.52% on the session (not supportive for micro/small-cap risk appetite).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $76.323M, essentially flat/slightly down YoY (-0.04%) → weak top-line momentum.
Profitability: Net income -$22.229M (improved 50.95% YoY) and EPS -0.32 (improved 33.33% YoY) → losses narrowing.
Gross margin: 34.51% (up 8.25% YoY) → improving unit economics, a genuine positive, but not yet translating into growth.
Overall: improving margins and smaller losses, but stagnant revenue keeps the equity story dependent on future re-acceleration.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: mostly Neutral/Hold/Equal Weight, with repeated price-target reductions.
2026-01-09 (Citi): PT cut to $2.75 from $3.25; kept Neutral.
2025-11-11 (Wells Fargo): PT cut to $5 from $6; kept Equal Weight; cautious on 2026 EBITDA.
2025-11-11 (Stifel): PT cut to $3.75 from $4.50; kept Hold; noted lack of near-term catalysts, opportunity mainly for longer-term investors.
2025-11-11 (Citi): PT cut to $3.25 from $3.50; kept Neutral.
Wall Street pros vs cons (implied): Pros = margin/EBITDA progression potential; Cons = limited near-term catalysts, cautious 2026 outlook, and valuation multiple constrained by growth uncertainty.

7 Analyst Rating

Wall Street analysts forecast HCAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCAT is 3.85 USD with a low forecast of 2.75 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

4 Hold

0 Sell

Moderate Buy

Current: 2.090

Low

2.75

Averages

3.85

High

Current: 2.090

Low

2.75

Averages

3.85

High

Citi

Neutral

downgrade

AI Analysis

2026-01-09

Reason

Citi

Price Target

AI Analysis

2026-01-09

downgrade

Neutral

Reason

Citi lowered the firm's price target on Health Catalyst to $2.75 from $3.25 and keeps a Neutral rating on the shares as part of the firm's 2026 outlook note on the health tech and distribution group. 2025 proved to be another challenging year for health tech, with nearly one-third of the group down greater than 25%, but the firm is "cautiously optimistic" looking ahead to 2026, the analyst tells investors.

Wells Fargo

Stan Berenshteyn

Equal Weight

downgrade

$6 -> $5

2025-11-11

Reason

Wells Fargo

Stan Berenshteyn

Price Target

$6 -> $5

2025-11-11

downgrade

Equal Weight

Reason

Wells Fargo analyst Stan Berenshteyn lowered the firm's price target on Health Catalyst to $5 from $6 and keeps an Equal Weight rating on the shares. The firm notes that Q3 slightly beat on one-offs, while 2025 was reaffirmed. Wells is "a bit more cautious" on 2026 EBITDA, but still sees meaningful progression.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HCAT

Unlock Now

HCAT Should I Buy

HCAT Should I Buy

Should You Buy Health Catalyst Inc (HCAT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch